DBCO-Hexanoyl-Val-Ala-PAB(m-PEG8)-Exatecan amine-acid 281 SMILES OCC#CC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 Purity (HPLC)

281 SMILES OCC#CC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 Purity (HPLC) >= 95% Shipping Conditions Room temperature Storage Conditions Refrigerated Shelf Life 12 months after the date of delivery Regulatory Statement For Research Use Only

393 SMILES BrCCOCCOCCOCCNC(=O)COC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 Purity (HPLC) >= 95% Shipping Conditions Room temperature Storage Conditions Refrigerated Shelf Life 12 months after the date of delivery Regulatory Statement For Research Use Only

55 SMILES [H][C@]12CS[C@@H](CCCCC(=O)NCCOCCOCCOCCN=[N+]=[N-])[C@@]1([H])NC(=O)N2 Purity (HPLC) >= 95% Shipping Conditions Room temperature Storage Conditions Refrigerated Shelf Life 12 months after the date of delivery Regulatory Statement For Research Use Only

1039/D4CB00184B

DBCO-Hexanoyl-Val-Ala-PAB(m-PEG8)-Exatecan amine-acid 281 SMILES OCC#CC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 Purity (HPLC)SOLU KNEX cleavable linker features a Val Ala dipeptide. m PEG8 is attached to the commonly used self immolative para aminobenzyl (PAB) moiety to increase aqueous solubility. The payload is Exatecan, a highly potent topoisomerase I inhibitor derived from camptothecin, which induces DNA damage by stabilizing the topoisomerase IDNA complex, resulting in cell cycle arrest and apoptosis. Derived from established ADC linker architectures, SOLU KNEX ADC